Latest news from
CNX Therapeutics

CNX Therapeutics is pleased to announce that it has successfully completed the acquisition of two CNS products from Sanofi SA, a global healthcare company.

CNX Therapeutics has secured its first debt facility from Credit funds managed by Ares Management, a global alternative investment manager.

CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.

CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.

CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.

CNX Therapeutics is delighted to announce that we have extended our strategic partnership with Venus Pharma by signing in-licensing deals for an additional five products. The agreements give CNX exclusive commercial rights to the products in the UK.

On Saturday 16th September, a day blessed by the last of the beautiful summer weather, a pioneering team of employees – none of whom have ever previously competed in any kind of sporting event – bravely represented CNX at the Impetus Private Equity Triathlon! By participating in the triathlon CNX raised money for Impetus, an organisation what works to transform the lives of young people from disadvantaged backgrounds by making sure they get the right support to succeed in school, in work and in life.

What is Pre-eclampsia?  Pre-eclampsia is a pregnancy complication characterised by high blood pressure and signs of damage to organ systems, most often the liver and kidneys. It usually begins after 20 weeks of pregnancy and in women whose blood pressure had previously been normal. Although less common, pre-eclampsia can also occur four to six weeks […]

August has been a very exciting month for CNX; we have welcomed four new faces to the team! Our recent product acquisitions mean it’s vital to have a talented and dynamic team in in place as we expand our portfolio and work towards our goal of becoming a leading provider of critical medicines. Joining our […]

London, August 10th 2023 – CNX Therapeutics Limited (“CNX Therapeutics”), a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients, is pleased to announce that it has successfully completed the acquisition of four cancer support products from Clinigen Limited (“Clinigen”), a global pharmaceutical services company. […]